A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis

Bone Marrow Transplantation

Volumn 37, Issue 4, 2006, Pages 353-358

  Nakamura, R ^a,c   Chakrabarti, S ^a   Akin, C ^b,d   Robyn, J ^b   Bahceci, E ^a,e   Greene, A ^a   Childs, R ^a   Dunbar, C E ^a   Metcalfe, D D ^b   Barrett, A J ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allogenic hematopoietic cell transplantation; Nonmyeloablative conditioning; Systemic mastocytosis

Indexed keywords

ADRENALIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; MESNA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD DONOR; CANCER CONTROL; CASE REPORT; CELL INFILTRATION; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FEMALE; FLUSHING; GENE ACTIVATION; GENE MUTATION; HISTOPATHOLOGY; HLA MATCHING; HUMAN; HUMAN CELL; HUMAN TISSUE; LONG TERM CARE; MALE; MAST CELL; MUTATIONAL ANALYSIS; NAUSEA; NONMYELOABLATIVE CONDITIONING; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; ONCOGENE C KIT; PILOT STUDY; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; SAFETY; SIBLING; SIDE EFFECT; SKIN TOXICITY; SYSTEMIC MASTOCYTOSIS; T LYMPHOCYTE; VOMITING;

ADULT; DISEASE PROGRESSION; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; MALE; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; RECURRENCE; SIBLINGS; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 32844466631     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705245     Document Type: Article

References (32)

1. Akin C,Metcalfe DD. Systemic mastocytosis. Annu Rev Med 2004; 55: 419-432.
2. Metcalfe DD, Akin C. Mastocytosis: Molecular mechanisms and clinical disease heterogeneity. Leuk Res 2001; 25: 577-582.
3. Jaffe E, Harris LH, Stein H, Vardiman J. Tumours of Hematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2001, pp. 49-55. Ref Type: Generic.
4. Valent P, Akin C, Sperr WR, Horny HP, Arock M, Lechner K et al. Diagnosis and treatment of systemic mastocytosis: State of the art. Br J Haematol 2003; 122: 695-717.
5. Przepiorka D, Giralt S, Khouri I, Champlin R, Bueso-Ramos C. Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: Review of forty cases. Am J Hematol 1998; 57: 24-28.
6. Ronnov-Jessen D, Lovgreen NP, Horn T. Persistence of systemic mastocytosis after allogeneic bone marrow transplantation in spite of complete remission of the associated myelodysplastic syndrome. Bone Marrow Transplant 1991; 8: 413-415.
7. Fodinger M, Fritsch G, Winkler K, Emminger W, Mitterbauer G, Gadner H et al. Origin of human mast cells: Development from transplanted hematopoietic stem cells after allogeneic bone marrow transplantation. Blood 1994; 84: 2954-2959.
8. Spyridonidis A, Thomas AK, Bertz H, Zeiser R, Schmitt-Graff A, Lindemann A et al. Evidence for a graft-versus-mast-cell effect after allogeneic bone marrow transplantation. Bone Marrow Transplant 2004; 34: 515-519.
9. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y et al. Identification of a Point Mutation in the Catalytic Domain of the Protooncogene c-kit in Peripheral Blood Mononuclear Cells of Patients who Have Mastocytosis with an Associated Hematologic Disorder. Proc Natl Acad Sci USA 1995; 92: 10560-10564.
10. Childs R, Clave E, Contentin D, Jayasekera D, Hensel N, Leitman S et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor chimerism precedes alloimmune responses. Blood 1999; 94: 3234-3241.
11. Sloand E, Childs RW, Solomon S, Greene A, Young NS, Barrett AJ. The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure hronic myelogenous leukemia. Bone Marrow Transplant 2003; 32: 897-901.
12. Nakamura R, Cortez K, Solomon S, Battiwalla M, Gill VJ, Hensel N et al. High-dose acyclovir and preemptive gancyclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 30: 235-242.
13. Au WY, Chan AC, Lie AK, Chen FE, Liang R, Kwong YL. Recurrent isolated extramedullary relapses as granulocytic sarcomas following allogeneic bone marrow transplantation for acute myeloid leukemia. Bone Marrow Transplant. 1998; 21: 205-208.
14. Lee KH, Lee JH, Kim S, Lee JS, Kim SH, Kim WK. High frequency of extramedullary relapse of acute leukemia after allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 26: 147-152.
15. Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, Van't Wout JW, Verhoef G, Gerritis WB et al. Cladribine therapy for systemic mastocytosis. Blood 2003; 102: 4270-4276.
16. Tefferi A, Li CY, Butterfield JH, Hoagland HC. Treatment of systemic mast-cell disease with cladribine. N Engl J Med 2001; 344: 307-309.
17. Pardanani A, Hoffbrand AV, Butterfield JH, Tefferi A. Treatment of systemic mast cell disease with 2-chlorodeoxy-adenosine. Leuk Res 2004; 28: 127-131.
18. Pardanani A, Elliott M, Reeder T, Li CY, Baxter EJ, Cross NC et al. Imatinib for systemic mast-cell disease. Lancet 2003; 362: 535-536.
19. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201-1214.
20. Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003; 101: 4660-4666.
21. Klion AD, Robyn J, Akin C, Noel P, Brown M, Law M et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2004; 103: 473-478.
22. Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD. A novel form of systemic mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004; 103: 3222-3225.
23. Corbin AS, Griswold IJ, La Rosee P, Yee KW, Heinrich MC, Reimer CL et al. Sensitivity of oncogeneic KIT mutants to the kinase inhibitors MLN518 and PD180970. Blood 2004; 104: 3754-3757.
24. Corbin AS, Demehri S, Griswold IJ, Wang Y, Metcalf III CA, Sundaranoorthi R et al. In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit. Blood 2005; 106: 227-234.
25. Growney JD, Clark JJ, Adelsperger J, Stone R, Fabbro D, Criffin JD et al. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 2005; 106: 721-724.
26. Gotlib J, Berube C, Growney JD, Chen CC, George TI, Williams C et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005; 106: 2865-2870.
27. Tanaka A, Konno M, Muto S, Kambe N, Morii E, Nakahata T et al. A novel NF-{kappa}B inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood 2005; 105: 2324-2331.
28. Fumo G, Akin C, Metcalfe DD, Neckers L. 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood 2004; 103: 1078-1084.
29. Hasford J, Pfirrmann M, Hochhaus A. How long will chronic myeloid leukemia patients treated with imatinib mesylate live? Leukemia 2005; 19: 497-499.
30. Stone RM. Optimizing treatment of chronic myeloid leukemia: A rational approach. Oncologist 2004; 9: 259-270.
31. Peggs K, Mackinnon S. Imatinib mesylate - the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 2003; 348: 1048-1050.
32. Druker BJ. Imatinib as a paradigm of targeted therapies. Adv Cancer Res 2004; 91: 1-30.